PharmacoEconomics - Open

2017 - 2025

Current editor(s): Timothy Wrightson and Christopher Carswell

From Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

Access Statistics for this journal.
Is something missing from the series or not right? See the RePEc data check for the archive and series.

Volume 4, issue 4, 2020

How Should a Safe and Effective COVID-19 Vaccine be Allocated? Health Economists Need to be Ready to Take the Baton pp. 557-561

Laurence Roope, John Buckell, Frauke Becker, Paolo Candio, Mara Violato, Jody L. Sindelar, Adrian Barnett, Raymond Duch and Philip M. Clarke

Brentuximab Vedotin for Treating Relapsed or Refractory CD30-Positive Cutaneous T-Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 563-574

Angela Stainthorpe, Nigel Fleeman, Rachel Houten, Marty Chaplin, Angela Boland, Sophie Beale, Yenal Dundar, Joanne McEntee and Isabel Syndikus

Cost-Effectiveness Analyses, Costs and Resource Use, and Health-Related Quality of Life in Patients with Follicular or Marginal Zone Lymphoma: Systematic Reviews pp. 575-591

Neerav Monga, Jamie Garside, Binu Gurung, Joan Quigley, Peter O’Donovan, Christoph Tapprich, Loretta Nastoupil, Catherine Thieblemont and Christina Loefgren

Economic Burden of the Out-of-Pocket Expenses for People with Multiple Sclerosis in France pp. 593-603

Olivier Heinzlef, Guillaume Molinier, Benoît Hille, Lise Radoszycki, Paul Dourgnon and Juliette Longin

Cost Analysis of the Automated Examination of Urine with the Sysmex UN-Series™ in a Spanish Population pp. 605-613

Óscar Herráez Carrera and María Del Monte Jarabo Bueno

A Multiple Stakeholder Multicriteria Decision Analysis in Diabetic Macular Edema Management: The MULTIDEX-EMD Study pp. 615-624

Fernando de Andrés-Nogales, Miguel Ángel Casado, José Luis Trillo, José María Ruiz-Moreno, José Manuel Martínez-Sesmero, Gemma Peralta, José Luis Poveda, Pere Ortiz, Emilio Ignacio, Javier Zarranz-Ventura, Patricia Udaondo, Carlos Mur, Eloísa Álvarez, Enrique Cervera, Mercedes Martínez, Iñaki Llorente, Jacinto Zulueta, Mariano Rodríguez-Maqueda, Alfredo García-Layana and José Martínez-Olmos

Empirical Monetary Valuation of a Quality-Adjusted Life-Year in the Kingdom of Saudi Arabia: A Willingness-to-Pay Analysis pp. 625-633

Shouki Bazarbashi, Edward B. De Vol, Fatma Maraiki, Ahmed Al-Jedai, Afshan A. Ali, Ali M. Alhammad, Ibrahim A. Aljuffali and Michael Iskedjian

Cost-Effectiveness Analysis of Sequential Biologic Therapy with Ixekizumab Versus Secukinumab in the Treatment of Active Psoriatic Arthritis with Concomitant Moderate-to-Severe Psoriasis in the UK pp. 635-648

Bernd Schweikert, Chiara Malmberg, Örjan Åkerborg, Gayathri Kumar, Debby Nott, Sandeep Kiri, Christophe Sapin and Susanne Hartz

Application of a Mapping Function to Estimate Utilities for Ragweed Allergy Immunotherapy Trials pp. 649-655

Katherine Dick, Andrew Briggs and Henrik Brandi

Observational Cost-Effectiveness Analysis Using Routine Data: Admission and Discharge Care Bundles for Patients with Chronic Obstructive Pulmonary Disease pp. 657-667

Padraig Dixon, William Hollingworth, Jonathan Benger, James Calvert, Melanie Chalder, Anna King, Stephanie MacNeill, Katherine Morton, Emily Sanderson and Sarah Purdy

The Budget Impact of Introducing Tildrakizumab to a United States Health Plan for Managing Moderate-to-Severe Plaque Psoriasis pp. 669-677

Justin Carrico, Yang Zhao, Xiaoying Jia, Thor-Henrik Brodtkorb, Alan Mendelsohn and Simon Lowry

A Corticosteroid-Eluting Sinus Implant Following Endoscopic Sinus Surgery for Chronic Rhinosinusitis: A UK-Based Cost-Effectiveness Analysis pp. 679-686

Mehdi Javanbakht, Hesham Saleh, Mohsen Rezaei Hemami, Michael Branagan-Harris and Margaret Boiano

Estimation of the Incremental Cumulative Cost of HIV Compared with a Non-HIV Population pp. 687-696

Joshua P. Cohen, Anne Beaubrun, Yao Ding, Rolin L. Wade and Dionne M. Hines

Is Protocolised Weaning that Includes Early Extubation Onto Non-Invasive Ventilation More Cost Effective Than Protocolised Weaning Without Non-Invasive Ventilation? Findings from the Breathe Study pp. 697-710

Iftekhar Khan, Mandy Maredza, Melina Dritsaki, Dipesh Mistry, Ranjit Lall, Sarah E. Lamb, Keith Couper, Simon Gates, Gavin D. Perkins and Stavros Petrou

Volume 4, issue 3, 2020

The Cost Effectiveness of Stockpiling Drugs, Vaccines and Other Health Resources for Pandemic Preparedness pp. 393-395

Pedro Plans-Rubió

Economic Evaluations of Pharmacological Treatments in Heart Failure Patients: A Methodological Review with a Focus on Key Model Drivers pp. 397-401

Gian Luca Di Tanna, Shuxian Chen, Anna Bychenkova, Heidi S. Wirtz, Karen L. Burrows and Gary Globe

Are Published Health Economic Models for Chronic Hepatitis B Appropriately Capturing the Benefits of HBsAg Loss? A Systematic Literature Review pp. 403-418

Peter Wigfield, Urbano Sbarigia, Mahmoud Hashim, Talitha Vincken and Bart Heeg

Benefit–Cost Analysis of the Danish Sun Safety Campaign 2007–2015: Cost Savings from Sunburn and Sunbed Use Reduction and Derived Skin Cancer Reductions 2007–2040 in the Danish Population pp. 419-425

Brian Køster, Maria K. H. Meyer, Jes Søgaard and Peter Dalum

Cost-Effectiveness of Sertraline in Primary Care According to Initial Severity and Duration of Depressive Symptoms: Findings from the PANDA RCT pp. 427-438

William Hollingworth, Christopher G. Fawsitt, Padraig Dixon, Larisa Duffy, Ricardo Araya, Tim J. Peters, Howard Thom, Nicky J. Welton, Nicola Wiles and Glyn Lewis

A Retrospective Claims Analysis of Advanced Prostate Cancer Costs and Resource Use pp. 439-447

Sreevalsa Appukkuttan, Krishna Tangirala, Svetlana Babajanyan, Lonnie Wen, Stacey Simmons and Neal Shore

Cost-Effectiveness Analysis of Nintedanib Versus Pirfenidone in Idiopathic Pulmonary Fibrosis in Belgium pp. 449-458

C. Rinciog, A. Diamantopoulos, A. Gentilini, B. Bondue, C. Dahlqvist, A. Froidure, W. A. Wuyts and S. Soulard

DyeVert™ PLUS EZ System for Preventing Contrast-Induced Acute Kidney Injury in Patients Undergoing Diagnostic Coronary Angiography and/or Percutaneous Coronary Intervention: A UK-Based Cost–Utility Analysis pp. 459-472

Mehdi Javanbakht, Mohsen Rezaei Hemami, Atefeh Mashayekhi, Michael Branagan-Harris, Azfar Zaman, Yahya Al-Najjar, Donal O’Donoghue, Farzin Fath-Ordoubadi and Stephen Wheatcroft

Treatment Satisfaction and Burden of Illness in Patients with Newly Diagnosed Multiple Myeloma pp. 473-483

Robert M. Rifkin, Jill A. Bell, Pronabesh DasMahapatra, Michael Hoole, Maria Lowe, Chris Curran, Scott Campbell, Peijie Hou and Dorothy Romanus

Cost-Effectiveness Analysis of Apixaban Versus Edoxaban in Patients with Atrial Fibrillation for Stroke Prevention pp. 485-497

Itziar Oyagüez, Carmen Suárez, José Luis López-Sendón, José Ramón González-Juanatey, Fernando Andrés-Nogales, Jorge Suárez, Carlos Polanco and Javier Soto

Cost Effectiveness of Antenatal Lifestyle Interventions for Preventing Gestational Diabetes and Hypertensive Disease in Pregnancy pp. 499-510

Cate Bailey, Helen Skouteris, Cheryce L. Harrison, Jacqueline Boyle, Rebeccah Bartlett, Briony Hill, Shakila Thangaratinam, Helena Teede and Zanfina Ademi

Self-Monitoring and Management of Blood Pressure in Patients with Stroke or TIA: An Economic Evaluation of TEST-BP, A Randomised Controlled Trial pp. 511-517

Lois G. Kim, Edward C. F. Wilson, William J. Davison, Allan B. Clark, Phyo K. Myint and John F. Potter

Burden of Cardiovascular Disease in Adult Patients with Type 1 Diabetes in the US pp. 519-528

Steve Edelman, Fang Liz Zhou, Ronald Preblick, Sumit Verma, Sachin Paranjape, Michael J. Davies and Vijay N. Joish

HSP27 Expression as a Novel Predictive Biomarker for Bevacizumab: is it Cost Effective? pp. 529-539

Mikyung Kelly Seo, Oddbjørn Straume, Lars A. Akslen and John Cairns

Metabolic Acidosis in Preterm Infants is Associated with a Longer Length of Stay in the Neonatal Intensive Care Unit pp. 541-547

Marika Paul, Jamie Partridge, Bridget Barrett-Reis, Kaashif A. Ahmad, Pattabhi Machiraju, Hemalatha Jayapalan and Richard J. Schanler

Comment on: “Systematic Review of Economic Evaluations in Primary Open-Angle Glaucoma: Decision Analytic Modeling Insights” pp. 549-550

Omar Salamanca

Authors’ Reply to Salamanca: “Systematic Review of Economic Evaluations in Primary Open Angle Glaucoma: Decision Analytic Modeling Insights” pp. 551-552

Jose Bartelt-Hofer and Steffen Flessa

Correction to: Benefit–Cost Analysis of the Danish Sun Safety Campaign 2007–2015: Cost Savings from Sunburn and Sunbed Use Reduction and Derived Skin Cancer Reductions 2007–2040 in the Danish Population pp. 553-554

Brian Køster, Maria K. H. Meyer, Jes Søgaard and Peter Dalum

Volume 4, issue 2, 2020

Learnings for Health Economics from the Early Stages of the COVID-19 Pandemic pp. 203-205

Anthony J. Hatswell

Group Testing for SARS-CoV-2: Forward to the Past? pp. 207-210

Koen B. Pouwels, Laurence Roope, Adrian Barnett, David J. Hunter, Terry M. Nolan and Philip M. Clarke

A Systematic Review of Model-Based Economic Evaluations of Treatments for Venous Leg Ulcers pp. 211-222

Ashley Layer, Emma McManus and N. J. Levell

Managing Uncertainties Due to Limited Evidence in Economic Evaluations of Novel Anti-Tuberculosis Regimens: A Systematic Review pp. 223-233

T. I. Armina Padmasawitri, Sarah Maria Saragih, Gerardus W. Frederix, Olaf Klungel and Anke M. Hövels

Cost Effectiveness of PD-L1-Based Test-and-Treat Strategy with Pembrolizumab as the First-Line Treatment for Metastatic NSCLC in Hong Kong pp. 235-247

Herbert H. Loong, Carlos K. H. Wong, Linda Kam Suet Leung, Praveen Dhankhar, Ralph P. Insinga, Sheenu Chandwani, Danny C. Hsu, Mary Y. K. Lee, Min Huang, James Pellissier, Akanksha Rai, Monika Achra and Seng Chuen Tan

Cost of Delivering Secondary Healthcare Through the Public Sector in India pp. 249-261

Shankar Prinja, Akashdeep Singh Chauhan, Pankaj Bahuguna, Sakhtivel Selvaraj, V. R. Muraleedharan and Thiagarajan Sundararaman

Touch for Health: Use of Pavlovian Processes with Physical Touch as a Means to Improve Menstrual Hygiene Management Initiatives, Measured by Willingness to Pay pp. 263-276

Siobhan Yilmaz, Alok Bohara and Soumi Roy Chowdhury

Cost-Effectiveness Analysis of Exenatide versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus pp. 277-286

Margarita Capel, Andreea Ciudin, María Mareque, Raquel María Rodríguez-Rincón, Susana Simón and Itziar Oyagüez

Health Technology Assessment of Drugs in Ireland: An Analysis of Timelines pp. 287-296

Emma Connolly, Helen O’Donnell, Felicity Lamrock, Lesley Tilson and Michael Barry

Economic Evaluation of Azacitidine in Elderly Patients with Acute Myeloid Leukemia with High Blast Counts pp. 297-305

D. Coyle and Pierre J. A. Villeneuve

Ticagrelor Removal by CytoSorb® in Patients Requiring Emergent or Urgent Cardiac Surgery: A UK-Based Cost-Utility Analysis pp. 307-319

Mehdi Javanbakht, Miranda Trevor, Mohsen Rezaei Hemami, Kazem Rahimi, Michael Branagan-Harris, Fabian Degener, Daniel Adam, Franziska Preissing, Jörg Scheier, Suzanne F. Cook and Eric Mortensen

Budget Impact Analysis of Metformin Sustained Release for the Treatment of Type 2 Diabetes in The Netherlands pp. 321-330

Judith J. Gout-Zwart, Lisa A. Jong, Lisanne Saptenno and Maarten J. Postma

Impact of a Clinical Pharmacist Intervention on Medicine Costs in Patients with Chronic Obstructive Pulmonary Disease in India pp. 331-342

Suhaj Abdulsalim, Mazhuvancherry Kesavan Unnikrishnan, Mohan K. Manu, Saud Alsahali, Alian A. Alrasheedy, Antony P. Martin, Brian Godman and Abubakr A. Alfadl

Modelling Survival of Patients Treated with Adjuvant Nivolumab Who Have Melanoma with Lymph Node Involvement or Metastatic Disease After Complete Resection pp. 343-351

Rachael Batteson, Rose Hart, Matthew Hemstock, Kyna Gooden, Srividya Kotapati, Stephane Roze, Dawn Lee and Adenike Amadi

The Costs of Industry-Sponsored Drug Trials in Canada pp. 353-359

Dat T. Tran, Ilke Akpinar and Philip Jacobs

A Nationwide Study of Prevalence Rates and Characteristics of 199 Chronic Conditions in Denmark pp. 361-380

Michael Falk Hvidberg, Soeren Paaske Johnsen, Michael Davidsen and Lars Ehlers

Treatment Patterns and Costs Associated with Stage IV Non-Small Cell Lung Cancer in a Mexican Population: A Chart Review pp. 381-388

Jorge Arturo Alatorre, Saúl Campos-Gómez, Emmanuel De la Mora, Diego Novick, Angélica Cruz and Jimena María Iglesias-Chiesa

Out-of-Pocket Cancer Care Costs and Value Frameworks: A Case Study in a Community Oncology Practice with a Financial Navigator Program pp. 389-392

Christine Leopold, Carina Araujo-Lane, Carol Rosenberg, Melissa Gilkey and Anita K. Wagner

Volume 4, issue 1, 2020

Registered Reports: Time to Radically Rethink Peer Review in Health Economics pp. 1-4

Philip Clarke, John Buckell and Adrian Barnett

Systematic Review of Economic Evaluations in Primary Open-Angle Glaucoma: Decision Analytic Modeling Insights pp. 5-12

Jose Bartelt-Hofer, Lilia Ben-Debba and Steffen Flessa

Health State Utility Data in Cystic Fibrosis: A Systematic Review pp. 13-25

Bishal Mohindru, David Turner, Tracey Sach, Diana Bilton, Siobhan Carr, Olga Archangelidi, Arjun Bhadhuri and Jennifer A. Whitty

The Health System Costs of Potentially Inappropriate Prescribing: A Population-Based, Retrospective Cohort Study Using Linked Health Administrative Databases in Ontario, Canada pp. 27-36

Cody D. Black, Kednapa Thavorn, Doug Coyle and Lise M. Bjerre

The Use of Computer Simulation Modeling to Estimate Complications in Patients with Type 2 Diabetes Mellitus: Comparative Validation of the Cornerstone Diabetes Simulation Model pp. 37-44

Zhuo T. Su, Jose Bartelt-Hofer, Stephen Brown, Elisheva Lew, Luc Sauriol, Lieven Annemans and Simon Grima

Cost-Effectiveness of Three Alternative Boosted Protease Inhibitor-Based Second-Line Regimens in HIV-Infected Patients in West and Central Africa pp. 45-60

S. Boyer, M. L. Nishimwe, L. Sagaon-Teyssier, L. March, S. Koulla-Shiro, Marwân-al-Qays Bousmah, R. Toby, M. P. Mpoudi-Etame, N. F. Ngom Gueye, A. Sawadogo, C. Kouanfack, L. Ciaffi, B. Spire and E. Delaporte

An Evaluation of Diagnosis-Related Group (DRG) Implementation Focused on Cancer DRGs in Greek Public Hospitals pp. 61-69

Panos Panagiotopoulos, Nikos Maniadakis, George Papatheodoridis and Dimitris Pektasidis

Return on Investment of Free Colorectal Cancer Screening Tests in a Primarily Rural Uninsured or Underinsured Population in Northeast Texas pp. 71-77

Gabriela Orsak, Anastasia Miller, Carlton M. Allen, Karan P. Singh and Paul McGaha

Cost Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in Colombia pp. 79-90

Hélène Parise, Robert Espinosa, Katherine Dea, Pablo Anaya, Giovanny Montoya and Daniel Bin Ng

Healthcare, Sickness Absence, and Disability Pension Cost Trajectories in the First 5 Years After Diagnosis with Multiple Sclerosis: A Prospective Register-Based Cohort Study in Sweden pp. 91-103

Korinna Karampampa, Hanna Gyllensten, Fei Yang, Chantelle Murley, Emilie Friberg, Jan Hillert and Kristina Alexanderson

Impact of Plan-Level Access Restrictions on Effectiveness of Biologics Among Patients with Rheumatoid or Psoriatic Arthritis pp. 105-117

Natalie Boytsov, Xiang Zhang, Kristin A. Evans and Barbara H. Johnson

US Integrated Delivery Networks Perspective on Economic Burden of Patients with Treatment-Resistant Depression: A Retrospective Matched-Cohort Study pp. 119-131

Dominic Pilon, Holly Szukis, Kruti Joshi, David Singer, John J. Sheehan, Jennifer W. Wu, Patrick Lefebvre and Paul Greenberg

Cost-Effectiveness Analysis of Recombinant Factor VIII Fc-Fusion Protein (rFVIIIFc) for the Treatment of Severe Hemophilia A in Italy Incorporating Real-World Dosing and Joint Health Data pp. 133-142

Ash Bullement, Samuel Thomas McMordie, Anthony James Hatswell, Nanxin Li and Koo Wilson

Early Economic Evaluation to Identify the Necessary Test Characteristics of a New Typhoid Test to be Cost Effective in Ghana pp. 143-157

Samuel N. Frempong, Andrew J. Sutton, Clare Davenport and Pelham Barton

A Cost-Effectiveness Analysis Comparing the VivaSight Double-Lumen Tube and a Conventional Double-Lumen Tube in Adult Patients Undergoing Thoracic Surgery Involving One-Lung Ventilation pp. 159-169

Sara Larsen, Jimmy Højberg Holm, Tove Nørgaard Sauer and Claus Andersen

Buccal Midazolam Solution for the Management of Prolonged Acute Convulsive Seizures: A Cost Analysis pp. 171-179

Catherine Ludwig and Lauri Fisher

Medical Costs of Patients with Type 2 Diabetes in a Single Payer System: A Classification and Regression Tree Analysis pp. 181-190

Paola Rucci, Vera Maria Avaldi, Claudio Travaglini, Cristina Ugolini, Elena Berti, Maria Luisa Moro and Maria Pia Fantini

Symptoms and Dietary Impact in Hypertriglyceridemia-Associated Pancreatitis: Development and Content Validity of Two New Measures pp. 191-201

Claire Burbridge, Jason A. Randall, Robert J. Sanchez, Hayes Dansky, Tara Symonds, Cynthia J. Girman, Joshua A. Strayer, Karen L. Selk, David C. Whitcomb and Erin E. Kershaw